NYSE:PFEPharmaceuticals
How Investors Are Reacting To Pfizer (PFE) Phase 2 Win For Tilrekimig In Atopic Dermatitis
Earlier in March 2026, Pfizer reported positive Phase 2 results for its investigational trispecific antibody tilrekimig in adults with moderate to severe atopic dermatitis, showing statistically significant EASI-75 responses versus placebo with a favorable safety profile across multiple monthly dosing regimens.
The data suggest tilrekimig could emerge as a differentiated, once-monthly option across several Type 2 inflammatory diseases, reinforcing Pfizer’s push into higher-value immunology...